Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
enGene TherapeuticsFRA:S0N0 -2.05%19 Net Margin % is 0.00% as of Apr. 2026. GuruFocus rates FRA:S0N0 with a GF Score™ of 19/100. The stock has 1 warning sign investors should review. Among 944 Biotechnology companies, enGene Therapeutics ranks worse than 105932.1% on this metric.
The historical rank and industry rank for enGene Therapeutics's Net Margin % or its related term are showing as below:
FRA:S0N0's Net Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -81.265 * Ranked among companies with meaningful Net Margin % only.
enGene Therapeutics (FRA:S0N0) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
enGene Therapeutics Net Margin % Related Terms
enGene Therapeutics Net Margin % Historical Data
* Premium members only.
The historical data trend for enGene Therapeutics's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:S0N0 vs VTVT, GUTS, VXRT: Net Margin % Comparison
For the Biotechnology subindustry, enGene Therapeutics's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
enGene Therapeutics Net Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, enGene Therapeutics's Net Margin % distribution charts can be found below:
* The bar in red indicates where enGene Therapeutics's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
enGene Therapeutics (FRA:S0N0) has a Net Margin % of 0.00% as of Apr. 2026. Net margin is the ratio of total net income to net sales. View historical data on enGene Therapeutics and its competitors. According to the industry distribution chart, enGene Therapeutics ranks #999999 out of 944 companies in the Biotechnology industry.
Is enGene Therapeutics' Net Margin % too high?
enGene Therapeutics' current Net Margin % is 0.00%. Based on the distribution chart, enGene Therapeutics ranks #999999 out of 944 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, enGene Therapeutics has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does enGene Therapeutics' Net Margin % compare to VTVT and GUTS?
According to the Biotechnology industry distribution chart, enGene Therapeutics ranks #999999 out of 944 companies for Net Margin %. This places enGene Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on enGene Therapeutics and its competitors. enGene Therapeutics's current Net Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is enGene Therapeutics stock overvalued right now?
enGene Therapeutics (FRA:S0N0) has a current Net Margin % of 0.00%. The current Net Margin % is 0.00%. enGene Therapeutics' overall GF Score™ is 19/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For enGene Therapeutics (FRA:S0N0), the current Net Margin % is 0.00% as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
enGene Therapeutics Inc is a clinical-stage biotechnology company mainstreaming gene therapy through the delivery of therapeutics to mucosal tissues and other organs, to create new ways to address diseases with high clinical needs. Its pioneering program is detalimogene voraplasmid (also known as detalimogene) for patients with Non-Muscle Invasive Bladder Cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase 2 trial, which includes a pivotal cohort studying detalimogene in high-risk, Bacillus Calmette-Guerin (BCG)-unresponsive patients with carcinoma in situ (CIS) with or without concomitant papillary disease. It is developed using enGene's proprietary Dually Derivatized Oligochitosan (DDX) platform.
19GF Score
Get the complete analysis for FRA:S0N0
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:S0N0 has been successfully added to your 
